Clinically, the most advanced of these BH3 mimetics is venetoclax, a selective inhibitor of BCL2, which has received approval by many regulatory authorities worldwide for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) [5, 6]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.